{"id":"NCT00195650","sponsor":"Abbott","briefTitle":"Long Term Open Label Continuation Study","officialTitle":"A Multi-Center Continuation Study of the Human Anti-TNF Antibody D2E7 Administered as a Subcutaneous Injection in Patients With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2000-07","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2005-09-20","resultsPosted":"2012-07-31","lastUpdate":"2012-08-31"},"enrollment":846,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["Humira, ABT-D2E7"]}],"arms":[{"label":"Adalimumab","type":"EXPERIMENTAL"}],"summary":"The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.","primaryOutcome":{"measure":"Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520","timeFrame":"Week 520","effectByArm":[{"arm":"Adalimumab","deltaMin":187,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":92,"countries":["United States","Canada"]},"refs":{"pmids":["26199453"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":432,"n":846},"commonTop":["Upper respiratory tract infection","Rheumatoid arthritis","Sinusitis","Nasopharyngitis","Bronchitis"]}}